Illumina on Thursday said the SEC has closed its investigation into the company's $8 billion purchase of Grail and doesn't ...

Takeda revealed a handful of pipeline cuts in its fourth-quarter earnings results on Thursday, as the company focuses its ...

Illumina estimates about $85 million in costs this year related to tariffs on its DNA sequencing products, the company said ...

AstraZeneca lost its challenge to Medicare drug price negotiations in the first appeals court ruling on the merits of the ...

The FDA is still reviewing a label expansion for GSK’s respiratory drug Nucala in chronic obstructive pulmonary disease ...

Boston-based Verastem Oncology on Thursday won accelerated approval from the FDA for Avmapki Fakzynja as a second-line ...

BMS commits $40B for US expansion, Shionogi buys Torii Pharma for $1.05B, Bavarian Nordic extends BARDA deal, multiple ...

Vor Bio, founded by famed cancer biologist Siddhartha Mukherjee, is looking for a way out. Its decision to pursue strategic ...

Fyodor Urnov and Kiran Musunuru advocate for streamlined CRISPR treatments for rare genetic diseases, partnering with Danaher ...

After working off $20 million in seed funding for about four years, HAYA Therapeutics tapped the funding well and came back ...